Developing safe oncolytic virus therapies
Ixogen Ltd is a UK based Biotechnology company focused on the research, development and commercialisation of safe and effective oncolytic viruses for the treatment of different types of cancers both on its own or in combination with other cancer treatments.
Ixogen was founded in 2011 by a team of distinguished specialists with vast experience in the virology, clinical/medical, pharmaceutical and financial disciplines. Our shared ethos is to help patients through the advancement of science, and we believe our first patented product Ixovex can have a transformative effect within the medical field.
We aim to revolutionise the way we treat cancer patients through our patented product portfolio of Adenoviruses, beginning with Ixovex which is a safe, modified Adenovirus developed in collaboration with Uppsala University in Sweden, which has demonstrated high efficacy.
Our pre-clinical phase lab work has yielded very exciting and promising results indicating our Ixovex platform has produced industry leading safety and tolerability profiles. We are now in the process of obtaining investment to progress to first phase human trials whilst continuing our research and development of our portfolio of treatments.
Key Personnel
Advisory Board Members
